Pharmaceutical and Pharmacological Sciences

Projects

Projects per year 1993 2015 2016 2018 2019 2020 2021 2022 2027

• 1 Not started
• 65 Active
• 91 Finished

Projects per year

Search results

• Active

  VLAIM5: Innovation mandate Spin-off: EVOZymes Development Platform

  Neuckermans, J., De Kock, J. & Vanhaecke, T.

  1/08/23 → 31/07/25

  Project: Applied

  • business planning 100%
  • in vivo studies 70%
  • animal models 56%
  • dosage 33%

• CONO773: Innovation Centre-3Rs Symposium 2023: ‘Emerging fields in 3Rs’

  Baert, Y., Rogiers, V. & Vanhaecke, T.

  1/08/23 → 31/12/23

  Project: Fundamental

  • toxicology 100%
  • bioprinting 67%
  • adolescence 59%
  • neurodevelopment 56%
  • applied research 54%

• BOR85: Brussels Research on Breastfeeding, Lactation and Technology

  Smolders, I. & Tommelein, E.

  1/07/23 → 31/12/23

  Project: Fundamental

  • candidiasis 100%
  • teats 68%
  • mastitis 53%
  • breast feeding 49%
  • breasts 47%

• AIIFUND104: An animal-free approach for human safety testing of food additives

  Vinken, M.

  11/04/23 → 30/04/25

  Project: Fundamental

  • Food additives 100%
  • Safety testing 86%
  • food additives 63%
  • Animals 53%
  • liver 21%

• ANI315: Understanding oncolytic herpes simplex virus type-1 induced cell death mechanisms and immunogenicity.

  Breckpot, K. & Kalus, P.

  1/01/23 → 31/12/23

  Project: Fundamental

  • Oncolytic Viruses 100%
  • Human Herpesvirus 1 79%
  • Cell Death 62%
  • Immunogenic Cell Death 24%
  • Oncolytic Virotherapy 15%

• FWOAL1076: Achiral and chiral targeted brain metabolomics in volume-limited samples: quest for broad coverage, sensitivity and throughput using chemical derivatization and miniaturized liquid chromatography tandem mass spectrometry.

  Van Eeckhaut, A. & Vander Heyden, Y.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Metabolite 100%
  • Chemometrics 36%
  • Enantiomer 27%
  • Volume 20%
  • Acid 12%

• AIIFUND101: In vitro implementation of a polygenic risk score for hepatic fat content (PRS-HFC) to unravel interindividual anti-NASH drug responses

  Vanhaecke, T. & Boeckmans, J.

  1/01/23 → 31/12/23

  Project: Fundamental

  • Fatty Liver 100%
  • Esterification 72%
  • Phospholipases 67%
  • Fats 59%
  • Protein Domains 56%

• FWOAL1070: The role of pannexin1 channels in non-alcoholic steatohepatitis: therapeutic and diagnostic relevance.

  Vinken, M.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Fatty Liver 100%
  • Coculture Techniques 13%
  • Therapeutics 9%
  • Paracrine Communication 9%
  • Inflammation 7%

• FWOAL1081: Organoids from transgender women testes: from medical waste to a promising testicular toxicity assay.

  Baert, Y.

  1/01/23 → 31/12/26

  Project: Fundamental

  • woman 100%
  • research project 99%
  • assay 89%
  • testes 86%
  • toxicity 77%

• FOD143: The development of an Integrated Approach to Testing and Assessment (IATA) for genotoxicity

  Vanhaecke, T.

  1/12/22 → 30/11/24

  Project: Fundamental

• OZR4018: OZR backup mandate: The influence of the gut microbiome on mRNA-based HIV-1 vaccination

  Aerts, J. & Cosyns, J.

  1/11/22 → 31/10/23

  Project: Fundamental

  • Gastrointestinal Microbiome 100%
  • Vaccination 70%
  • HIV-1 66%
  • Messenger RNA 50%
  • Viruses 42%

• FWOTM1143: Do microplastics and nanoplastics induce and/or exacerbate liver cancer? A combined in vitro-in vivo study

  Vinken, M. & De Boever, S.

  1/11/22 → 31/10/26

  Project: Fundamental

  • nanoplastics 100%
  • microplastics 82%
  • liver neoplasms 40%
  • hepatocytes 10%
  • translational medical research 9%

• FWOSB134: Development and application of a human stem cell-derived, etiology-based anti-MAFLD drug discovery platform targeting the thyroid hormone receptor axis

  Vanhaecke, T., Boeckmans, J., Marcelino Rodrigues, R. & Gatzios, A.

  1/11/22 → 31/10/26

  Project: Fundamental

  • methamidophos 100%
  • Non-alcoholic Fatty Liver Disease 98%
  • Thyroid Hormone Receptors 91%
  • Drug Discovery 86%
  • Phospholipases 67%

• OZR4013: OZR backup mandate: Mechanistic investigation of the liver cholestatic effects of PFAS: a combined in vitro-in vivo study.

  Vinken, M. & Maerten, A.

  1/11/22 → 31/10/23

  Project: Fundamental

  • cholestasis 100%
  • bile 70%
  • per- and polyfluoroalkyl substances 63%
  • liver 59%
  • translational medical research 52%

• ANI334: Francqui-Chair VUB - Academic Year 2022-2023: appointed to - Prof. dr. Johan Neyts , KU Leuven

  Aerts, J.

  1/10/22 → 30/09/23

  Project: Fundamental

  • Antiviral Agents 100%
  • Virology 60%
  • Belgium 54%
  • Enterovirus 53%
  • Dengue 53%

• FWOTM1095: System xc- as metabolic regulator in the aging brain

  Ates, G. & Massie, A.

  1/10/22 → 30/09/25

  Project: Fundamental

  • Brain 100%
  • Oocytes 95%
  • Energy Metabolism 92%
  • Lactic Acid 90%
  • Oxygen 72%

• SRP86: SRP-Groeifinanciering: Unravelling host-pathogen-immune interactions in infectious diseases: the good, the bad and the ugly

  Allard, S. & Aerts, J.

  1/10/22 → 30/09/27

  Project: Fundamental

  • Communicable Diseases 100%
  • Host-Pathogen Interactions 95%
  • Pandemics 23%
  • Vaccines 21%
  • Allergy and Immunology 15%

• SRP85: SRP-Onderzoekszwaartepunt: Translating the biology of cognitive function to improve diagnosis and treatment of brain disorders

  Smolders, I., De Bundel, D., Van Eeckhaut, A., Engelborghs, S., Massie, A., Nagels, G. & Van Schependom, J.

  1/10/22 → 30/09/27

  Project: Fundamental

  • Brain Diseases 100%
  • Cognition 94%
  • Cognitive Dysfunction 61%
  • Multiple Sclerosis 26%
  • Epilepsy 25%

• VLIR418: Levodopa-rich biomass of slime molds and puffballs and their melanins for treatment of Parkinson’s disease and Alzheimer’s disease

  Van Eeckhaut, A.

  1/09/22 → 31/08/27

  Project: Fundamental

  • L-dopa 100%
  • Parkinson disease 97%
  • Melanin 89%
  • Alzheimer disease 88%
  • melanin 78%

• OZR4032: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - MUST (Uganda), TUYIRINGIRE Naasson

  Vander Heyden, Y.

  3/03/22 → 2/03/26

  Project: Fundamental

  • Uganda 100%

• EUAR77: VORTEXLC : Vortex enhanced liquid chromatography for HbA1c monitoring based diabetes management in a globalized setting

  De Malsche, W., Ottevaere, H. & Weets, I.

  1/03/22 → 28/02/26

  Project: Applied

  • Hemoglobins 100%
  • Point-of-Care Systems 23%
  • Liquid Chromatography 21%
  • Diabetes Complications 20%
  • Health Status 17%

• AIIFUND87: Study Abroad Program Ministry of National Education - Turkey: Ph.D. Batuhan Yildiz

  Vinken, M. & Yildiz, B.

  1/02/22 → 31/12/25

  Project: Policy Based

  • RNA Sequencing 100%
  • Phalloidin 96%
  • Activation Analysis 81%
  • Apolipoprotein 73%
  • studies abroad 69%

• FOD119: An Interdisciplinary strategy to identify medical devices as a source of allergic or pyrogenic reactions

  Vanhaecke, T.

  17/01/22 → 16/01/24

  Project: Fundamental

  • Pyrogenic 100%
  • Budgets 77%
  • Hypersensitivity 55%
  • Equipment and Supplies 40%

• FWOAL1042: Investigating the role of astrocytes and noradrenaline as critical regulators of neuronal circuit excitability.

  De Bundel, D.

  1/01/22 → 31/12/25

  Project: Fundamental

  • Norepinephrine 100%
  • Astrocytes 93%
  • Brain 24%
  • Neurotransmitter Agents 14%
  • Epilepsy 14%

• FWOAL1047: Can food additives cause liver damage? A mechanistic in vitro modelling study.

  Vinken, M.

  1/01/22 → 31/12/25

  Project: Fundamental

  • food additives 100%
  • Netherlands 42%
  • liver 34%
  • hepatocytes 13%
  • sweeteners 8%

• FWOAL1041: Combination of Molecular Dynamics and Quantitative Structure Enantioselective Relationships (QSER) models to elucidate enantiorecognition mechanisms on polysaccharide and antibiotic based chiral selectors

  Mangelings, D., Vanommeslaeghe, K. & Vander Heyden, Y.

  1/01/22 → 31/12/25

  Project: Fundamental

  • Polysaccharide 100%
  • Enantiomer 91%
  • Antimicrobial Agent 82%
  • Molecular Dynamics 73%
  • Pharmaceutical 61%

• IOFCOFUN1: IOF strategic cofinancing.

  Thienpont, H., Westbroek, P., Ivcevic, A., Thumfart, J., Leiva, C. L., Outsios, G., Chichevaliev, S., Mampay, M., Teixeira-Costa, L., Mihajlovic, M., Parvez, M. S. & Chen, Y.

  15/12/21 → 15/12/25

  Project: Applied

• OZR3923: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UGent, DE BOEVER Sybren

  Vinken, M.

  17/11/21 → 16/11/25

  Project: Fundamental

• FWOTM1078: PiKachU: Development of human phenylalanine ammonia lyase (PAL) enzymes to treat phenylketonuria (PKU) using directed protein evolution

  Nulmans, I. & De Kock, J.

  1/11/21 → 31/10/23

  Project: Fundamental

  • Phenylalanine Ammonia-Lyase 100%
  • Phenylketonurias 71%
  • Human Development 60%
  • Enzymes 30%
  • Proteins 20%

• FWOTM1061: Chemogenetic modulation of CX3CR1+ cells in a mouse model of drug-resistant limbic epilepsy.

  Bossuyt, J. & Smolders, I.

  1/11/21 → 31/10/23

  Project: Fundamental

  • Designer Drugs 100%
  • Microglia 84%
  • Drug Resistant Epilepsy 71%
  • Astrocytes 57%
  • Neurosciences 55%

• OZR3898: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UGent, MAERTEN Amy

  Vinken, M.

  13/10/21 → 12/10/25

  Project: Fundamental

• VLOV157: Virtual Lab, development of higher order lab skills

  Van Eeckhaut, A.

  1/10/21 → 15/10/23

  Project: Fundamental

  • software 100%

• OZRSRF43: Connexins, pannexins and their channels as drug targets and biomarkers of liver disease and toxicity

  Vinken, M.

  1/10/21 → 30/09/26

  Project: Fundamental

  • Biomarkers 100%
  • Toxicity 78%
  • Drugs 59%

• VLAOO18: O&O Project HOBOTA - High dimensional Organoid Based organ Toxicity Assessment

  Vinken, M.

  1/09/21 → 30/06/24

  Project: Applied

• OZR3867: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UAntwerpen, ROBBERECHTS Anneleen

  Steurbaut, S.

  24/08/21 → 23/08/25

  Project: Fundamental

• OZR3879: H2020: Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment (OZR EU BONUS)

  Vinken, M.

  1/05/21 → 30/04/26

  Project: Fundamental

  • Artificial Intelligence 100%
  • toxicity testing 78%
  • risk assessment 77%
  • Risk Assessment 62%
  • artificial intelligence 44%

• EUAR61: H2020: Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment

  Vinken, M., Vanhaecke, T. & Rogiers, V.

  1/05/21 → 30/04/26

  Project: Fundamental

  • Artificial Intelligence 100%
  • Risk Assessment 62%
  • risk assessment 58%
  • testing of chemicals 40%
  • toxicity 37%

• OZRMETH6: Cellular communication as target and biomarker in liver disease and toxicity: from basic research towards clinical application

  Vinken, M.

  1/01/21 → 31/12/27

  Project: Fundamental

  • Liver Diseases 100%
  • Budgets 67%
  • Biomarkers 57%
  • Connexins 46%
  • Liver 15%

• ANI281: Role of neurogenesis in cognitive decline following stroke in co-morbid Alzheimer's dementia

  De Bundel, D., Kooijman, R., Gens, R. & De Smet, A.

  1/01/21 → 31/10/24

  Project: Fundamental

  • stroke 100%
  • dementia 87%
  • budget 68%
  • Stroke 59%
  • Alzheimer Disease 57%

• FWOWO39: Hepatic toxicity modeling and prediction: focus on drug-induced cholestasis

  Vinken, M.

  1/01/21 → 31/12/25

  Project: Fundamental

  • Toxicity 100%
  • credit 18%
  • drug 14%
  • Group 6%

• FWOAL1003: TALENT: Engineering human tyrosine ammonia lyase (TAL) enzymes to treat inborn errors of tyrosine metabolism

  De Kock, J.

  1/01/21 → 31/12/24

  Project: Fundamental

  • L-tyrosine ammonia-lyase 100%
  • Tyrosine 62%
  • Inborn Errors Metabolism 55%
  • Ergonomics 45%
  • Enzymes 34%

• FWOSB107: “Next Generation Risk Assessment” (NGRA) to assess the genotoxicity of chemical compounds without the use of experimental animals.

  Thienpont, A. & Vanhaecke, T.

  1/11/20 → 31/10/24

  Project: Fundamental

  • risk assessment 100%
  • genotoxicity 93%
  • chemical compounds 68%
  • laboratory animals 67%
  • risk assessment process 54%

• OZR3565: Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization system

  Massie, A., Stiens, J., Van Ginderachter, J., Vanommeslaeghe, K., Vinken, M., Menu, E., Spits, C. & Njemini, R.

  1/05/20 → 30/04/24

  Project: Fundamental

  • syrosingopine 100%
  • Multiple Myeloma 99%
  • AMP-Activated Protein Kinases 59%
  • Metformin 53%
  • Smegmamorpha 48%

• HERC53: Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization system

  Massie, A., Stiens, J., Van Ginderachter, J., Vanommeslaeghe, K., Vinken, M., Menu, E., Spits, C. & Njemini, R.

  1/05/20 → 30/04/24

  Project: Fundamental

  • syrosingopine 100%
  • Multiple Myeloma 99%
  • AMP-Activated Protein Kinases 59%
  • Metformin 53%
  • Smegmamorpha 48%

• OZR3585: Financiering FWO Hercules: Exploiting high aspect ratio etching processes of glass and dielectric materials to enable novel chemical, analytical, optical, and medical applications

  De Malsche, W., Hubin, A., Hellemans, K., Maes, D., Vander Heyden, Y., Stiens, J., Desmet, G. & Peeters, E.

  1/05/20 → 30/04/24

  Project: Fundamental

  • etching 100%
  • high aspect ratio 85%
  • glass 46%
  • arts 16%
  • tapering 14%

• OZR3588: Financiering FWO hercules: ERA platform: Extended RNA Analysis platform - version 2.0

  Rooman, I., Bouwens, L., Heimberg, H., Neyns, B., Vranken, W., Vanhaecke, T., Massie, A., van Grunsven, L., De Bruyne, E., De Bundel, D., Forsyth, R., Breckpot, K., Van Dooren, S., De Kock, J., Njemini, R. & Laoui, D.

  1/05/20 → 30/04/24

  Project: Fundamental

  • Tissue 100%
  • RNA 85%
  • Gene expression 51%
  • Histology 34%
  • Antibodies 29%

• OZR3528: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UAntwerpen, NOUS Amber

  Smolders, I.

  5/03/20 → 4/03/24

  Project: Fundamental

• EU624: Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.

  Vinken, M. & Ballet, S.

  European Commission

  1/03/20 → 31/08/24

  Project: Fundamental

  • Connexins 100%
  • Joint Diseases 88%
  • Cardiovascular Diseases 58%
  • Liver 41%
  • Antiinflammatory 38%

• OZR3516:  Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - UAntwerpen, VANDE VYVER Maxime

  Smolders, I.

  6/02/20 → 5/02/24

  Project: Fundamental

• FWOAL974: Development of a novel nanoparticle formulation for mRNA based therapeutic vaccination

  Aerts, J.

  1/01/20 → 31/12/23

  Project: Fundamental

  • Messenger RNA 100%
  • Caveolae 80%
  • Vaccination 74%
  • Nanoparticles 73%
  • Endocytosis 62%